# Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

> **NCT00592163** · PHASE1 · UNKNOWN · sponsor: **Alaunos Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** ZIO-101-C (Darinaparsin)

## Key facts

- **NCT ID:** NCT00592163
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592163, "Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00592163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*